Labial salivary gland biopsy for diagnosing immunoglobulin light chain amyloidosis: a retrospective analysis
- 300 Downloads
Our goal was to evaluate the usefulness of labial salivary gland (LSG) biopsy for diagnosing immunoglobulin light chain (AL) amyloidosis, by comparing bone marrow and skin biopsies in the same patient population. This retrospective study included 34 consecutive patients who showed evidence of monoclonal proteins and symptoms considered to be due to amyloidosis, and who underwent a tissue biopsy from LSG between January 2005 and December 2012 at Nagoya City University Hospital. All samples of superficial tissues, including LSG, bone marrow, and skin, were independently evaluated as having amyloid deposits by a central review, which was blind to clinical information. An AL amyloidosis diagnosis was based on evidence of amyloid deposition in any biopsied tissue. Eighteen patients were diagnosed with AL amyloidosis. The sensitivity for detecting amyloid deposition was highest in biopsies of LSG at 89 %, followed by 77 % for bone marrow, and 72 % for skin. Amyloid deposition was detected in at least one superficial tissue of all the 18 patients. An LSG biopsy may be appropriate as a first-choice procedure to diagnose AL amyloidosis. Multiple biopsies of superficial tissues, including LSG, bone marrow, and skin, are recommended to increase the sensitivity for diagnosing AL amyloidosis.
KeywordsAL amyloidosis Labial salivary gland Bone marrow Skin Superficial tissue biopsy
Compliance with ethical standards
This study was supported in part by the Amyloidosis Research Committee from the Ministry of Health, Labour and Welfare, Japan.
Conflict of interest
Shinsuke Iida has received research funding from Bristol-Myers Squibb Co., Chugai Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., Celgene K.K., Kyowa Hakko Kirin Co. Ltd., Ono Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Nippon Kayaku Co. Ltd., and honoraria from Celgene K.K., Janssen Pharmaceutical K.K. and Ono Pharmaceutical Co. Ltd.
Takashi Ishida has received research funding from Kyowa Hakko Kirin Co., Ltd., Bayer Pharma AG, and Celgene K.K., and honoraria from Kyowa Hakko Kirin Co., Ltd.
Ethics approval and consent to participate
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. For this type of retrospective study, formal consent was not required.
- 1.Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, Merlini G, Moreau P, Ronco P, Sanchorawala V, Sezer O, Solomon A, Grateau G (2005) Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18–22 April 2004. Am J Hematol 79(4):319–328. doi: 10.1002/ajh.20381 PubMedCrossRefGoogle Scholar
- 5.Hachulla E, Janin A, Flipo RM, Saile R, Facon T, Bataille D, Vanhille P, Hatron PY, Devulder B, Duquesnoy B (1993) Labial salivary gland biopsy is a reliable test for the diagnosis of primary and secondary amyloidosis. A prospective clinical and immunohistologic study in 59 patients. Arthritis Rheum 36(5):691–697PubMedCrossRefGoogle Scholar
- 7.Foli A, Palladini G, Caporali R, Verga L, Morbini P, Obici L, Russo P, Sarais G, Donadei S, Montecucco C, Merlini G (2011) The role of minor salivary gland biopsy in the diagnosis of systemic amyloidosis: results of a prospective study in 62 patients. Amyloid 18(Suppl 1):80–82. doi: 10.3109/13506129.2011.574354029 PubMedCrossRefGoogle Scholar
- 11.Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar SK, Dingli D, Ansell SM, Gastineau DA, Inwards DJ, Johnston PB, Litzow MR, Micallef IN, Porrata LF, Leung N, Hogan WJ, Buadi FK (2010) Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report. Leuk Lymphoma 51(12):2181–2187. doi: 10.3109/10428194.2010.524329 PubMedCrossRefGoogle Scholar
- 13.Stoopler ET, Vogl DT, Alawi F, Greenberg MS, Sollecito TP, Salazar G, Stadtmauer EA (2011) The presence of amyloid in abdominal and oral mucosal tissues in patients initially diagnosed with multiple myeloma: a pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 111(3):326–332. doi: 10.1016/j.tripleo.2010.10.028 PubMedCrossRefGoogle Scholar
- 16.Comenzo RL, Zhou P, Fleisher M, Clark B, Teruya-Feldstein J (2006) Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins. Blood 107(9):3489–3491. doi: 10.1182/blood-2005-10-4148 PubMedCrossRefGoogle Scholar
- 18.Gilbertson JA, Theis JD, Vrana JA, Lachmann H, Wechalekar A, Whelan C, Hawkins PN, Dogan A, Gillmore JD (2015) A comparison of immunohistochemistry and mass spectrometry for determining the amyloid fibril protein from formalin-fixed biopsy tissue. J Clin Pathol 68(4):314–317. doi: 10.1136/jclinpath-2014-202722 PubMedCrossRefGoogle Scholar
- 21.Schonland SO, Hegenbart U, Bochtler T, Mangatter A, Hansberg M, Ho AD, Lohse P, Rocken C (2012) Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients. Blood 119(2):488–493. doi: 10.1182/blood-2011-06-358507 PubMedCrossRefGoogle Scholar